

COMT Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP10956a**Specification**

COMT Antibody (N-term) Blocking peptide - Product Information

Primary Accession [P21964](#)

COMT Antibody (N-term) Blocking peptide - Additional Information

Gene ID 1312

Other Names

Catechol O-methyltransferase, COMT

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

COMT Antibody (N-term) Blocking peptide - Protein Information

Name COMT ([HGNC:2228](#))

Function

Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.

Cellular Location

[Isoform Soluble]: Cytoplasm

Tissue Location

Brain, liver, placenta, lymphocytes and erythrocytes

COMT Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

COMT Antibody (N-term) Blocking peptide - Images

COMT Antibody (N-term) Blocking peptide - Background

Catechol-O-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine. This O-methylation results in one of the major degradative pathways of the catecholamine transmitters. In addition to its role in the metabolism of endogenous substances, COMT is important in the metabolism of catechol drugs used in the treatment of hypertension, asthma, and Parkinson disease. COMT is found in two forms in tissues, a soluble form (S-COMT) and a membrane-bound form (MB-COMT). The differences between S-COMT and MB-COMT reside within the N-termini. Several transcript variants are formed through the use of alternative translation initiation sites and promoters.

COMT Antibody (N-term) Blocking peptide - References

Paloyelis, Y., et al. Neuropsychopharmacology 35(12):2414-2426(2010) Stroth, S., et al. Neurobiol Learn Mem 94(3):364-372(2010) Lim, J.H., et al. Pharmacogenet. Genomics 20(10):605-610(2010) Demetrovics, Z., et al. Compr Psychiatry 51(5):510-515(2010) Bodenmann, S., et al. Sleep 33(8):1027-1035(2010)